Aytu Biopharma (AYTU) EBITDA Margin (2013 - 2026)

Aytu Biopharma (AYTU) has 14 years of EBITDA Margin data on file, last reported at 32.75% in Q1 2026.

• EBITDA Margin for Q1 2026 came in at 32.75%, down 4587.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 18.08% (down 1431.0% YoY), and the FY2025 annual result was 4.36%, down 192.0% from the prior year.
• EBITDA Margin retreated to 32.75% in Q1 2026 per AYTU's latest filing, from 12.99% in the prior quarter.
• Over five years, EBITDA Margin peaked at 254.32% in Q2 2022 and troughed at 220.76% in Q1 2022.
• A 5-year average of 4.98% and a median of 10.83% in 2025 frame the typical range for EBITDA Margin.
• The sharpest annual moves came in 2022 and 2023: EBITDA Margin jumped 35684 bps in 2022, then plunged 20990 bps in 2023.
• A 5-year view of EBITDA Margin shows it stood at 26.13% in 2022, then jumped by 164 bps to 16.78% in 2023, then plunged by 162 bps to 10.45% in 2024, then slipped by 24 bps to 12.99% in 2025, then tumbled by 152 bps to 32.75% in 2026.
• Business Quant data shows AYTU's EBITDA Margin at 32.75% in Q1 2026, 12.99% in Q4 2025, and 10.83% in Q3 2025.